Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

While the number of patients within each cohort is limited for such analyses, there was a clear trend indicating an inferior relapse‐free as well as disease‐specific survival for patients with concomitant inactivation of both the p53‐and the RB‐pathway, in both cohorts ( Figure 7 ).

also in 19,460 other papers